探索未知领域:确定糖尿病视网膜病变新型药理疗法的知识差距

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
Amin Sharifan, Sobha Sivaprasad
{"title":"探索未知领域:确定糖尿病视网膜病变新型药理疗法的知识差距","authors":"Amin Sharifan, Sobha Sivaprasad","doi":"10.1038/s41433-024-03349-x","DOIUrl":null,"url":null,"abstract":"<p>Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].</p><p>Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring the unexplored: identifying knowledge gaps in novel pharmacological treatments for diabetic retinopathy\",\"authors\":\"Amin Sharifan, Sobha Sivaprasad\",\"doi\":\"10.1038/s41433-024-03349-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].</p><p>Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41433-024-03349-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03349-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

摘要

糖尿病视网膜病变是一种可导致糖尿病黄斑水肿或视力丧失的严重疾病。2020 年,全球约有 1.03 亿至 1.12 亿糖尿病患者受到视网膜病变的影响。预计到 2030 年和 2045 年,这一数字将分别增至 1.29-84 亿和 1.60-50 亿。虽然抗血管内皮生长因子治疗改善了糖尿病视网膜病变患者的视觉效果,但有报告显示,有些患者的糖尿病黄斑水肿并没有完全消除,大多数患者需要多次注射和长期治疗。这些局限性激发了人们对能更有效控制糖尿病视网膜病变的新型药物的兴趣[2]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Exploring the unexplored: identifying knowledge gaps in novel pharmacological treatments for diabetic retinopathy

Exploring the unexplored: identifying knowledge gaps in novel pharmacological treatments for diabetic retinopathy

Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].

Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信